Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X

CAS 911705-40-3 manufacturers and suppliers on PharmaCompass

PharmaCompass
CAS	911705-40-3
Also known as: 911705-40-3, 3-oxo-2-phenyl-piperazine-1-carboxylic acid tert-butyl ester, Schembl2539220, 1-boc-3-oxo-2-phenylpiperazine, Xwyogpgttfwzap-uhfffaoysa-n, Cs-d0486
Molecular Formula
C15H20N2O3
Molecular Weight
276.33  g/mol
InChI Key
XWYOGPGTTFWZAP-UHFFFAOYSA-N

1 2D Structure

CAS	911705-40-3

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
tert-butyl 3-oxo-2-phenylpiperazine-1-carboxylate
2.1.2 InChI
InChI=1S/C15H20N2O3/c1-15(2,3)20-14(19)17-10-9-16-13(18)12(17)11-7-5-4-6-8-11/h4-8,12H,9-10H2,1-3H3,(H,16,18)
2.1.3 InChI Key
XWYOGPGTTFWZAP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)OC(=O)N1CCNC(=O)C1C2=CC=CC=C2
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 911705-40-3

2. 3-oxo-2-phenyl-piperazine-1-carboxylic Acid Tert-butyl Ester

3. Schembl2539220

4. 1-boc-3-oxo-2-phenylpiperazine

5. Xwyogpgttfwzap-uhfffaoysa-n

6. Cs-d0486

7. Mfcd28579819

8. Akos027255478

9. As-68179

10. W10309

11. Tert-butyl3-oxo-2-phenylpiperazine-1-carboxylate

2.3 Create Date
2012-11-30
3 Chemical and Physical Properties
Molecular Weight 276.33 g/mol
Molecular Formula C15H20N2O3
XLogP31.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count3
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area58.6
Heavy Atom Count20
Formal Charge0
Complexity370
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Flag South Korea
Digital Content Digital Content
URL Supplier Web Content
23612-57-9
Mirtazapine
ESTECHPHARMA CO.,LTD., as one of the active pharmaceutical company, is remarkably growing more than 30% e...
ESTECHPHARMA CO.,LTD., as one of the active pharmaceutical company, is remarkably growing more than 30% every year by concentrating all our efforts into developing new technologies by investing more than 15% of the annual turnover into R&D since our foundation in 1996. That is company ideology, challenge and creation. We've succeeded in synthesizing 40 kinds of APIs like Anti-inflammatory medicine, Anti-ulcerants, Anti-hepatitis, Treatments of Alcoholism, and etc secondly or thirdly in the world or firstly in Korea, and have been producing and supplying continuously to our customers.
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY